Arcturus Therapeutics And CSL Announce Results Of Head-To-Head Study Showing Self-Amplifying mRNA COVID-19 Vaccine Demonstrated Superior Immune Response Compared With mRNA Vaccine At 12 Months Post-Vaccination
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics and CSL have announced that their self-amplifying mRNA COVID-19 vaccine showed a superior immune response compared to a standard mRNA vaccine 12 months after vaccination.
September 30, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine demonstrated a superior immune response compared to a standard mRNA vaccine 12 months post-vaccination, potentially boosting investor confidence.
The positive results from the head-to-head study could lead to increased investor confidence in Arcturus Therapeutics, potentially driving up the stock price. The superior performance of their vaccine may also enhance their competitive position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90